In last trading session, Leap Therapeutics Inc (NASDAQ:LPTX) saw 0.34 million shares changing hands with its beta currently measuring -0.19. Company’s recent per share price level of $0.40 trading at $0.01 or 1.73% at ring of the bell on the day assigns it a market valuation of $16.50M. That closing price of LPTX’s stock is at a discount of -1097.5% from its 52-week high price of $4.79 and is indicating a premium of 45.0% from its 52-week low price of $0.22. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.34 million shares which gives us an average trading volume of 2.55 million if we extend that period to 3-months.
For Leap Therapeutics Inc (LPTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.38 in the current quarter.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Leap Therapeutics Inc’s shares saw a change of -86.09% in year-to-date performance and have moved 10.04% in past 5-day. Leap Therapeutics Inc (NASDAQ:LPTX) showed a performance of -11.82% in past 30-days. Number of shares sold short was 3.81 million shares which calculate 0.72 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5.5 to the stock, which implies a rise of 92.73% to its current value. Analysts have been projecting 5.5 as a low price target for the stock while placing it at a high target of 5.5. It follows that stock’s current price would drop -1275.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1275.0% for stock’s current value.
Leap Therapeutics Inc (LPTX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 30.39% while estimates for its earnings growth in next 5 years are of 23.83%.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
Insiders are in possession of 3.24% of company’s total shares while institution are holding 48.62 percent of that, with stock having share float percentage of 50.25%. Investors also watch the number of corporate investors in a company very closely, which is 48.62% institutions for Leap Therapeutics Inc that are currently holding shares of the company. BALYASNY ASSET MANAGEMENT L.P. is the top institutional holder at LPTX for having 3.1 million shares of worth $6.08 million. And as of 2024-06-30, it was holding 7.9238 of the company’s outstanding shares.
The second largest institutional holder is SAMSARA BIOCAPITAL, LLC, which was holding about 2.44 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.2428 of outstanding shares, having a total worth of $4.79 million.
On the other hand, Simplify Exchange Traded Funds-Simplify Health Care ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 946.05 shares of worth $0.38 million or 2.29% of the total outstanding shares. The later fund manager was in possession of 754.74 shares on Dec 31, 2024 , making its stake of worth around $0.3 million in the company or a holder of 1.83% of company’s stock.
